Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Unilever plc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.47B), while Unilever plc trades at $64.89 (market cap $137.84B). The key difference: Unilever plc is far larger — about 16.3× Hinge Health Inc. Class A Common Stock's market cap, and Unilever plc pays a 3.32% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Unilever plc for 112 Days on average.
| HNGE | UL | |
|---|---|---|
Market Cap | $8.47B | $137.84B |
Volume | 1,624,526 | 2,711,415 |
Sector | Health | Consumer Staples |
52-Week High | $105.14 | $74.59 |
52-Week Low | $31.17 | $55.05 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $8.09B | $162.87B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Unilever (UL) trades at $62.49, down 0.73% with a bullish technical signal despite recent earnings misses. The company shows strong profitability with 18.32% net margins and 54.56% ROE, though revenue declined to $50.5B in 2025. Recent news highlights the planned $65B food business merger with McCormick facing regulatory scrutiny while the company focuses on beauty and personal care segments.
UL presents a mixed outlook with strong fundamentals offset by execution risks. The 26.32% buy rating and $66.08 consensus target suggest modest upside potential, but investors face headwinds from competitive pressures and integration challenges from the McCormick deal. The stock's current valuation at 21.87 P/E appears reasonable given its defensive characteristics and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
